Tryton Medical to Present Pivotal Clinical Data on Dedicated Bifurcation Stent at TCT 2015

Company will host lunch symposium to highlight implications of findings on treatment of coronary bifurcation lesions on Tuesday, October 13th at 11:30am PDT.

DURHAM, N.C.--()--Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced the company will present results from the Tryton Confirmatory Study, a pivotal single-arm clinical trial evaluating use of the Tryton Side Branch Stent in patients with coronary bifurcation lesions involving side branches that are 2.25mm in diameter or greater. Results will be presented at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF) to be held October 11-15, 2015 in San Francisco, Calif.

Tryton Confirmatory Study results will be presented by Dr. Philippe Généreux, director of the Angiographic Core Laboratory at the CRF Clinical Trials Center, as part of the “Featured Clinical Research I: Presentations to the Editors of the Journal of the American College of Cardiology” session on Monday, October 12th at 1:30pm PDT.

Tryton will also host a lunch symposium to review the findings and the implications for clinical practice on Tuesday, October 13th at 11:30am PDT. The symposium will be co-chaired by Dr. Martin Leon, director of the Center for Interventional Vascular Therapy at Columbia University Medical Center, New York-Presbyterian Hospital, and Dr. Dean Kereiakes, medical director for the Christ Hospital Heart and Vascular Center and the Carl and Edyth Lindner Center for Research and Education.

In addition, the Tryton Side Branch Stent will be the subject of a case study presentation and a number of poster abstracts during the meeting. The complete schedule for Tryton at TCT 2015 is as follows:

Monday, October 12

  • Featured Clinical Research, 1:30pm - 1:40pm PDT
    Moscone South, Lower Level, Room 104
    The TRYTON PIVOTAL: Randomized Trial and Confirmatory Study
    Dedicated Bifurcation Stent in Coronary Bifurcation Involving Large Side Branches
  • Dedicated Systems for Specific Lesion Subsets, 5:03pm - 6:10pm PDT
    Moscone West, 3rd Floor, Room 3001 – 3005
    Case 5: Bifurcations or Left Main – The Tryton Stent

Tuesday, October 13

  • Tryton Lunch Symposium, 11:30am - 12:30pm PDT
    Moscone South, Lower Level, Exhibit Hall, Presentation Theater 4
    TRYTON PIVOTAL: Randomized Trial and Confirmatory Study
    Implications for Everyday Practice
  • Poster abstracts, 4:00pm – 6:00pm PDT
    Moscone West, 1st Floor
  • 2-Year Clinical Follow-up of the TRYTON IDE Randomized Trial
  • Incidence of Peri-Procedural MI: Insight from the Tryton IDE Randomized Trial
  • Detailed Segmental Comparison Using IVUS and 3D QCA: a Subgroup Analysis of the Tryton IDE Randomized Trial

Wednesday, October 14

  • Next Generation DES Technology: Let the Future Begin! 6:00pm - 8:00pm PDT
    Ballroom Level, Continental Ballroom 1-4
    Customized Stents to Treat Different Anatomical and Clinical Scenarios
    Bifurcations, MI, Small Vessels, and More

Tryton will also be exhibiting at booth #1317. For news and updates from Tryton throughout TCT 2015, follow @TrytonMedical1 and the hashtag #BuiltForBifurcation on Twitter.

About Tryton Side Branch Stent

Tryton Side Branch Stent System is built using proprietary Tri-ZONE® technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single wire balloon-expandable stent delivery system. A conventional drug eluting stent is then placed in the main vessel. Tryton Side Branch Stent has now been used to treat more than 11,000 patients worldwide. The Tryton Side Branch Stent is commercially available in multiple countries within Europe, Middle East & Africa, is investigational in the US, and is not available in Japan.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is the leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D., professor of medicine at Dartmouth Medical School/Dartmouth-Hitchcock Medical Center, to develop stents for the definitive treatment of bifurcation lesions. For more information please visit www.trytonmedical.com and follow the company on Twitter at @TrytonMedical1.

Contacts

Tryton Medical, Inc.
Judy Gonzalez, 919-226-1490
jgonzalez@trytonmedical.com

Contacts

Tryton Medical, Inc.
Judy Gonzalez, 919-226-1490
jgonzalez@trytonmedical.com